Pharmaceutical firms Elan and Biogen have reported progress in the development of their multiple sclerosis drug Tysabri.
The phase 3 Tysabri Affirm monotherapy trial achieved the two-year primary end-point of slowing the progression of disability in patients with relapsing forms of multiple sclerosis, the companies said in a research update released today.
The trial data showed that Tysabri led to a 42 per cent reduction in the risk of disability progression compared to the placebo.
The data also showed a 67 per cent reduction in the rate of clinical relapse over two years. The incidence of side effects at two years was similar to previous reported results.
